Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Esflurbiprofen Topical System (TK-254RX) vs Oral Flurbiprofen
NCT06823284Phase 1Completed
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esflurbiprofen in Musculoskeletal pain, acute pain and osteoarthritis (OA) (2 arms), sponsored by Teikoku Seiyaku Co., Ltd. Primary endpoints: Area under the plasma concentration versus time curve over 24 hours of S-flurbiprofen under steady-state conditions, Peak Plasma Concentration of S-flurbiprofen under steady-state conditions and 1 more. Started Jan 2025; status: completed.
02
Drugs
esflurbiprofen
03
Conditions
Musculoskeletal painacute painosteoarthritis (OA)
Beyond the preview
Go deeper on NCT06823284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823284.